We Work for Health | Washington

03/11/2026

"Today's drug pricing proposals overlook this fragile balance. If Medicare price controls or MFN models drive down reimbursement rates while acquisition costs stay the same — or climb higher due to tariffs — independent practices will be left underwater."

https://www.nola.com/opinions/guest_columns/guest-column-drug-pricing-reforms-cannot-neglect-independent-practitioners/article_03ea9366-87d9-40f9-a2ca-127fabba76c1.html

03/10/2026

"It would be a tragic mistake for the U.S. to move forward with a well-intentioned but flawed plan to tie drug prices to European health systems where QALY-based cost-effectiveness frameworks influence pricing and reimbursement decisions."

https://www.thewellnews.com/opinions/dont-adopt-europes-discriminatory-drug-pricing-against-individuals-with-down-syndrome/

03/06/2026

"China is dramatically expanding biotech funding and commercialization through state-backed programs, while Europe pairs aggressive price controls with heavy public investment in life sciences infrastructure."

policy won't work for the U.S.:

By failing to account for the true cost and risk of medical innovation, MFN would undermine investment, slow research, and jeopardize jobs, patients, and our position as a global leader

03/04/2026

"CBO originally estimated that the Center for Medicare and Medicaid Innovation would save $2.8 billion from 2011 to 2020, but the bureaucracy ended up costing taxpayers $5.4 billion."

More on the "Taxpayer's State of the Union":

The state of the union is far better than it was under President Biden.

03/02/2026

Voters have made their voices heard about the importance of transparency and access.

Here's what they said: https://www.americasnewmajorityproject.net/p/insurer-and-middleman-crackdowns?utm_source=post-email-title&publication_id=6887949&post_id=189143946&utm_campaign=email-post-title&isFreemail=false&r=16tk4&triedRedirect=true&utm_medium=email

02/27/2026

"By seeking to anchor US prices to international benchmarks, however, the proposals create a fundamental policy tension between US safeguards against use of QALYs in Medicare, and the adoption of QALY-based decisions from other countries."

https://www.healthaffairs.org/content/forefront/qaly-paradox-unintended-consequence-most-favored-nation-drug-pricing

02/25/2026

Remember, government price-setting risks shifting leadership in biotech innovation from the U.S. to other countries.

Read about the possible impacts in this op-ed by Rich Bagger of Drug Wonks:

Republican U.S. Rep. Nicole Malliotakis has consistently raised concerns about the dangers of onerous federal regulations that stifle innovation and economic

02/25/2026

The State of the Union made it clear: Drug pricing is on President Donald J. Trump's mind.

Instead of ensuring low prices make it to patients, Most Favored Nation drug pricing could halt innovation and catapult China to international leadership in biopharma.

02/23/2026

Today, the U.S. is on the cutting edge of the life sciences.

drug pricing risks our global leadership, stalling new discoveries for cancer treatment and other disease areas.

More from We Work for Health:

According to a recent report from the American Cancer Society, the five-year survival rate for cancer in the United States has significantly improved.In the mid-1970s, only half of cancer patients would survive five years or more, now seven in 10 survive.Thanks to technological innovation leading to...

02/20/2026

Over $582 billion has been committed to U.S. infrastructure in the past year.

Track the biopharma investments shaping state economies with We Work for Health’s Biopharma Investment Watch:

We Work For Health brings together national and local business leaders, labor, biopharma, patient advocacy, and other healthcare-related stakeholders to support policies and initiatives that foster innovation and facilitate the delivery of lifesaving and life-enhancing medicines.

02/18/2026

: Europe is approving more new drugs, but it still trails the U.S.

This is the result of MFN-style pricing. Price controls slow access to innovation. As the U.S. considers MFN, Europe’s experience is a warning.

From We Work for Health:

After several years of steady growth, Europe’s drug regulators are once again increasing the pace of recommended medicines for approval. Last year, European authorities recommended 38 new active substances, delivering a second straight year of elevated output. Even so, Europe continues to lag well...

02/18/2026

This month, Washington Post's editorial board broke down a U.S. biopharma ecosystem that is under threat from the IRA, MFN drug pricing, and intensifying competition with China.

Analysis is clear: Decisive correction is needed.

China is on track to become the world’s pharmaceutical leader if the U.S. keeps blowing its edge.